Soon-Shiong's NantCell raises $75M

NantCell Inc. raised $75 million in an equity financing from a single investor, according to an SEC filing. NantCell, which did not respond to inquiries, is one of several subsidiaries of Patrick Soon-Shiong's NantWorks LLC.

In January, NantCell licensed exclusive, worldwide rights excluding Japan to ganitumab ( AMG 479), a human mAb antagonist of insulin-like growth factor-1 ( IGF-1) receptor ( IGF1R), from Amgen Inc. (NASDAQ:AMGN). NantCell had said it would investigate the compound's potential to treat multiple cancers based on molecular profiling. Amgen had studied it in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC), and terminated a Phase III pancreatic cancer study of the candidate in 2012. ...